General
Preferred name
ALAPROCLATE
Synonyms
Alaproclatum ()
ALAPROCLATE HYDROCHLORIDE ()
NSC-758657 ()
GEA-654 ()
GEA 654 ()
Alaproclate HCl ()
Alaproclate (hydrochloride) ()
P&D ID
PD014535
CAS
60719-82-6
60719-83-7
Tags
drug candidate
natural product
available
Drug indication
Antidepressant
Drug Status
experimental
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Potent and selective serotonin reuptake inhibitor (LOPAC library)
DESCRIPTION Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s. Development was discontinued due to concerns over hepatotoxicity observed in animal studies. Alaproclate is a selective serotonin reuptake inhibitor (SSRI) and inhibits depletion of a serotonin (5-HT) induced by 4-methyl-α-methyl-m-tyramine in rat cerebral cortex, hippocampus, hypothalamus and striatum. It has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine. Alaproclate inhibits NMDA-evoked currents and depolarization-induced voltage-dependent potassium currents in rat hippocampal neurons. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
3
Compound Sets
9
Cayman Chemical Bioactives
ChEMBL Drugs
DrugBank
DrugMatrix
Ki Database
LOPAC library
NPC Screening Collection
ReFrame library
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
255.1
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
2.55
TPSA
52.32
Fraction CSP3
0.46
Chiral centers
1.0
Largest ring
6.0
QED
0.84
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
Reuptake
Source data